Flash Finance

Speciality Medicines Ltd544738Corporate

Latest results: Mar 2026 2 quarters of data
—
MCap —
Live price not available
Speciality Medicines Ltd — Stock analysis & AI research Speciality Medicines Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹45 Cr
Sales · Mar 2026
+45.2% YoY
₹8 Cr
Operating Profit · Mar 2026
+100.0% YoY
17.8%
OPM % · Mar 2026
+38.0% YoY
₹8 Cr
Net Profit · Mar 2026
+166.7% YoY
₹9.31
EPS · Mar 2026
+123.8% YoY

📝 Speciality Medicines Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Speciality Medicines Ltd reported revenue of ₹45 crore for the quarter ended March 2026 (Q4 FY26), up 45.2% from ₹31 crore in the same quarter last year.

Net profit rose 166.7% year-on-year to ₹8 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹9.31.

Operating profit stood at ₹8 crore — an operating margin (OPM) of 17.8%, compared with 12.9% in the year-ago quarter.

Shareholding pattern

As of Mar 2026, promoters held 43.43%, foreign institutional investors (FIIs) 0.24%, public shareholders 56.34% of Speciality Medicines Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
N/A
Current Price ?
N/A
P/E ?
N/A
Industry P/E ?
N/A
P/B ?
N/A
P/S ?
N/A
P/FCF ?
N/A
Enterprise Value ?
N/A
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
25.0%
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹45 Cr
PAT — latest qtr ?
₹8 Cr
YoY qtr sales growth ?
45.2%
YoY qtr profit growth ?
166.7%
Sales growth (3y) ?
48%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
98%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹7 Cr
Debt to Equity ?
0.10
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
43.43%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
N/A
Return 6 months ?
N/A

🗓️ Quarterly results (2 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2025Mar 2026 YoY % QoQ %
Sales 3145 +45.2% —
Operating Profit 48 +100.0% —
Other Income 01 — —
Interest 01 — —
Depreciation 00 — —
Profit Before Tax 48 +100.0% —
Net Profit 38 +166.7% —
EPS 4.169.31 +123.8% —
OPM % 12.9% 17.8% +38.0% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 4569 +50.0%
Reserves 2102462 +158.3%
Borrowings 4357 +40.0%
Other Liabilities 45517 +240.0%
Total Liabilities 13234095 +137.5%
Fixed Assets 2122 +0.0%
CWIP 0000 —
Investments 0000 —
Other Assets 11213893 +144.7%
Total Assets 13234095 +137.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -4-5-6-1 +83.3%
Cash from Investing Activity 0-0-2-3 -50.0%
Cash from Financing Activity 45828 +250.0%
Net Cash Flow 0-0124 +2300.0%
Free Cash Flow -4-5-6-1 +83.3%
CFO/OP -101%-66%-63%-9% +85.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 8714260128 +113.3%
Inventory Days 103161150191 +27.3%
Days Payable 4048880 +900.0%
Cash Conversion Cycle 149255202239 +18.3%
Working Capital Days 76185180221 +22.8%
ROCE % 52%38%34%25% -26.5%

👥 Shareholding (latest 1 periods)

Metric Mar 2026 % Chg
Promoters 43.43% —
FIIs 0.24% —
Public 56.34% —
No. of Shareholders 757 —

⚖️ Peer comparison

Peer comparison unavailablePeer comparison unavailable — industry and sector are not classified for this symbol.
❓ Frequently asked questions
What was Speciality Medicines Ltd's revenue in Q4 FY26?
Speciality Medicines Ltd reported revenue of ₹45 crore for the quarter ended March 2026 (Q4 FY26), up 45.2% from ₹31 crore in the same quarter last year.
What was Speciality Medicines Ltd's net profit in Q4 FY26?
Net profit rose 166.7% year-on-year to ₹8 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹9.31.
Who owns Speciality Medicines Ltd? (shareholding pattern)
As of Mar 2026, promoters held 43.43%, foreign institutional investors (FIIs) 0.24%, public shareholders 56.34% of Speciality Medicines Ltd.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI